Corrado Advisors LLC Sells 3,896 Shares of Harrow Health, Inc. (NASDAQ:HROW)

Corrado Advisors LLC cut its stake in shares of Harrow Health, Inc. (NASDAQ:HROW) by 27.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,521 shares of the company’s stock after selling 3,896 shares during the period. Corrado Advisors LLC’s holdings in Harrow Health were worth $118,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Allspring Global Investments Holdings LLC bought a new position in Harrow Health during the 3rd quarter valued at $26,000. Stonehage Fleming Financial Services Holdings Ltd bought a new stake in shares of Harrow Health during the 3rd quarter worth $34,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Harrow Health by 347.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,063 shares of the company’s stock worth $46,000 after purchasing an additional 3,155 shares during the period. Swiss National Bank raised its stake in shares of Harrow Health by 5.5% during the 3rd quarter. Swiss National Bank now owns 65,400 shares of the company’s stock worth $940,000 after purchasing an additional 3,400 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of Harrow Health by 3.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 188,825 shares of the company’s stock worth $2,713,000 after purchasing an additional 5,981 shares during the period. 72.76% of the stock is currently owned by institutional investors.

Insider Activity at Harrow Health

In related news, CEO Mark L. Baum bought 9,000 shares of Harrow Health stock in a transaction on Friday, March 22nd. The stock was acquired at an average price of $11.59 per share, with a total value of $104,310.00. Following the acquisition, the chief executive officer now directly owns 2,137,525 shares of the company’s stock, valued at $24,773,914.75. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CEO Mark L. Baum bought 9,000 shares of Harrow Health stock in a transaction on Friday, March 22nd. The stock was acquired at an average price of $11.59 per share, with a total value of $104,310.00. Following the acquisition, the chief executive officer now directly owns 2,137,525 shares of the company’s stock, valued at $24,773,914.75. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Opaleye Management Inc. bought 29,400 shares of Harrow Health stock in a transaction on Friday, April 19th. The shares were bought at an average cost of $10.56 per share, with a total value of $310,464.00. Following the acquisition, the insider now directly owns 3,775,000 shares in the company, valued at $39,864,000. The disclosure for this purchase can be found here. In the last three months, insiders have bought 139,000 shares of company stock worth $1,544,064. Company insiders own 13.60% of the company’s stock.

Harrow Health Stock Performance

Harrow Health stock traded down $0.28 during midday trading on Tuesday, reaching $10.32. The stock had a trading volume of 661,080 shares, compared to its average volume of 443,815. Harrow Health, Inc. has a 12 month low of $7.60 and a 12 month high of $28.25. The firm’s 50-day moving average price is $11.60 and its 200 day moving average price is $11.30. The firm has a market capitalization of $364.92 million, a PE ratio of -13.76 and a beta of 0.48. The company has a quick ratio of 2.61, a current ratio of 2.83 and a debt-to-equity ratio of 2.60.

Harrow Health (NASDAQ:HROW) last announced its quarterly earnings data on Tuesday, March 19th. The company reported ($0.27) earnings per share (EPS) for the quarter. Harrow Health had a negative net margin of 18.75% and a negative return on equity of 29.48%. The firm had revenue of $36.36 million during the quarter, compared to the consensus estimate of $37.65 million. As a group, research analysts predict that Harrow Health, Inc. will post -0.39 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on HROW shares. B. Riley lowered their target price on Harrow Health from $30.00 to $26.00 and set a “buy” rating on the stock in a research note on Friday, March 22nd. Craig Hallum started coverage on Harrow Health in a research note on Thursday, April 11th. They set a “buy” rating and a $24.00 target price on the stock.

Harrow Health Company Profile

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.